High Discontinuation Rates for Weight Loss Drugs Due to Cost

A recent study reveals that nearly 65% of individuals who attempted to lose weight using the popular GLP-1 medications such as Ozempic and Victoza discontinued their usage within a year. Those without Type 2 diabetes showed the highest quit rates, likely due to high costs and limited insurance coverage, as many insurers do not pay for these drugs when prescribed for weight loss. Medical records from over 125,000 adults indicate that financial factors, along with side effects, significantly impact patients' decisions to continue or cease using these weight loss aids.

The study underscores that individuals with higher incomes who experience fewer side effects are more likely to remain on the drugs. In contrast, patients with diabetes have shown higher continuance rates. The research also highlights that many employers offer limited health insurance for obesity drugs, leading to further access issues for patients. While plans to expand coverage are in discussion, significant barriers to the affordability and accessibility of these medications persist, risking widening health disparities.

Researchers stress the need for improved insurance policies to support patients in managing obesity effectively. The Biden administration's plans to extend obesity drug coverage to Medicare and Medicaid enrollees starting in 2026 may help alleviate some of these challenges, but the feasibility of this initiative remains to be seen. The study points out that without addressing the issues of cost and accessibility, many patients may be unable to take advantage of the potential benefits of these medications.